PALO ALTO, Calif.--(BUSINESS WIRE)--Carmenta Bioscience, Inc., in collaboration with researchers at Stanford University, today announced presentation of results from a retrospective clinical study at the 2013 Society of Maternal Fetal Medicine national meeting. The presentation revealed a new confirmatory diagnostic test highly accurate in distinguishing mothers with preeclampsia from a control group in the study. The underlying technology for the test was discovered by Carmenta’s co-founders, Dr. Atul Butte and Dr. Bruce Ling of Stanford University. Dr. Butte and Dr. Ling analyzed genomic and proteomic data from over 100 preeclamptic mothers to develop a novel, proprietary panel of serum proteins capable of diagnosis. Using advanced data mining techniques, they identified a multiplexed panel of biomarkers representing the broad diversity of biological processes associated with the condition.
